High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.

Purpose: High-dose-rate (HDR) brachytherapy used as the only treatment (monotherapy) for early prostate cancer is consistent with current concepts in prostate radiobiology, and the dose is reliably delivered in a prospectively defined anatomic distribution that meets all the requirements for safe and effective therapy. We report the disease control and toxicity of HDR monotherapy from California Endocurietherapy (CET) and William Beaumont Hospital (WBH) in low- and intermediate-risk prostate cancer patients.

Methods And Materials: There were 298 patients with localized prostate cancer treated with HDR monotherapy between 1996 and 2005.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Purpose: Prostate cancer patients treated with high dose rate brachytherapy and external beam radiation therapy were stratified by risk group for analysis to determine whether androgen deprivation therapy (ADT) affected outcome.

Methods: From 1991 through 1998, 411 patients were treated with 4 fractions of 5.5 to 6.